25 XP   0   0   10

OBI Pharma
Buy, Hold or Sell?

Let's analyse OBI Pharma together

PenkeI guess you are interested in OBI Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of OBI Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about OBI Pharma

I send you an email if I find something interesting about OBI Pharma.

Quick analysis of OBI Pharma (30 sec.)










What can you expect buying and holding a share of OBI Pharma? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$21.61
Expected worth in 1 year
NT$16.45
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
NT$-5.16
Return On Investment
-8.8%

For what price can you sell your share?

Current Price per Share
NT$58.50
Expected price per share
NT$0 - NT$65.20
How sure are you?
50%

1. Valuation of OBI Pharma (5 min.)




Live pricePrice per Share (EOD)

NT$58.50

Intrinsic Value Per Share

NT$20.24 - NT$27.58

Total Value Per Share

NT$41.85 - NT$49.19

2. Growth of OBI Pharma (5 min.)




Is OBI Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$152.5m$198.2m-$21.6m-12.2%

How much money is OBI Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$8m-$12.4m$4.3m54.2%
Net Profit Margin-5,997.4%-48,150.3%--

How much money comes from the company's main activities?

3. Financial Health of OBI Pharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#301 / 1016

Most Revenue
#578 / 1016

Most Profit
#512 / 1016

Most Efficient
#921 / 1016

What can you expect buying and holding a share of OBI Pharma? (5 min.)

Welcome investor! OBI Pharma's management wants to use your money to grow the business. In return you get a share of OBI Pharma.

What can you expect buying and holding a share of OBI Pharma?

First you should know what it really means to hold a share of OBI Pharma. And how you can make/lose money.

Speculation

The Price per Share of OBI Pharma is NT$58.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of OBI Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in OBI Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$21.61. Based on the TTM, the Book Value Change Per Share is NT$-1.29 per quarter. Based on the YOY, the Book Value Change Per Share is NT$2.47 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of OBI Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.07-0.1%-0.010.0%-0.05-0.1%-0.04-0.1%-0.04-0.1%
Usd Book Value Change Per Share-0.07-0.1%-0.04-0.1%0.080.1%0.000.0%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-0.1%-0.04-0.1%0.080.1%0.000.0%0.030.1%
Usd Price Per Share2.14-2.54-2.69-3.39-3.46-
Price to Earnings Ratio-7.59-2.30--13.63--15.39--15.71-
Price-to-Total Gains Ratio-28.80--15.04--5.16--38.86--36.63-
Price to Book Ratio3.21-3.30-3.10-4.87-5.02-
Price-to-Total Gains Ratio-28.80--15.04--5.16--38.86--36.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.8018
Number of shares555
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.00
Usd Total Gains Per Share-0.040.00
Gains per Quarter (555 shares)-22.051.79
Gains per Year (555 shares)-88.197.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-88-9807-3
20-176-1860144
30-265-27402111
40-353-36202918
50-441-45003625
60-529-53804332
70-617-62605039
80-706-71405746
90-794-80206453
100-882-89007260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%2.019.00.09.5%2.019.00.09.5%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%7.014.00.033.3%7.014.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%7.014.00.033.3%7.014.00.033.3%

Fundamentals of OBI Pharma

About OBI Pharma

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 22:05:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of OBI Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit OBI Pharma earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • A Net Profit Margin of -2,846.9% means that NT$-28.47 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of OBI Pharma:

  • The MRQ is -2,846.9%. The company is making a huge loss. -2
  • The TTM is -5,997.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,846.9%TTM-5,997.4%+3,150.6%
TTM-5,997.4%YOY-48,150.3%+42,152.8%
TTM-5,997.4%5Y-56,193.0%+50,195.5%
5Y-56,193.0%10Y-60,463.2%+4,270.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,846.9%-197.2%-2,649.7%
TTM-5,997.4%-210.4%-5,787.0%
YOY-48,150.3%-279.3%-47,871.0%
5Y-56,193.0%-436.8%-55,756.2%
10Y-60,463.2%-599.3%-59,863.9%
1.1.2. Return on Assets

Shows how efficient OBI Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • -9.4% Return on Assets means that OBI Pharma generated NT$-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of OBI Pharma:

  • The MRQ is -9.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.4%TTM-4.4%-5.0%
TTM-4.4%YOY-5.9%+1.5%
TTM-4.4%5Y-6.2%+1.8%
5Y-6.2%10Y-6.3%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.4%-13.6%+4.2%
TTM-4.4%-12.9%+8.5%
YOY-5.9%-11.9%+6.0%
5Y-6.2%-14.2%+8.0%
10Y-6.3%-16.2%+9.9%
1.1.3. Return on Equity

Shows how efficient OBI Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • -13.8% Return on Equity means OBI Pharma generated NT$-0.14 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of OBI Pharma:

  • The MRQ is -13.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.8%TTM-6.7%-7.1%
TTM-6.7%YOY-8.0%+1.3%
TTM-6.7%5Y-8.2%+1.6%
5Y-8.2%10Y-8.3%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.8%-17.0%+3.2%
TTM-6.7%-16.1%+9.4%
YOY-8.0%-15.4%+7.4%
5Y-8.2%-20.0%+11.8%
10Y-8.3%-21.1%+12.8%

1.2. Operating Efficiency of OBI Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient OBI Pharma is operating .

  • Measures how much profit OBI Pharma makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of OBI Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,400.7%+1,400.7%
TTM-1,400.7%YOY-59,910.8%+58,510.1%
TTM-1,400.7%5Y-53,837.2%+52,436.5%
5Y-53,837.2%10Y-59,023.7%+5,186.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-1,400.7%-224.4%-1,176.3%
YOY-59,910.8%-288.4%-59,622.4%
5Y-53,837.2%-475.2%-53,362.0%
10Y-59,023.7%-624.7%-58,399.0%
1.2.2. Operating Ratio

Measures how efficient OBI Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 29.20 means that the operating costs are NT$29.20 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of OBI Pharma:

  • The MRQ is 29.198. The company is inefficient in keeping operating costs low. -1
  • The TTM is 100.395. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ29.198TTM100.395-71.197
TTM100.395YOY610.975-510.581
TTM100.3955Y630.642-530.248
5Y630.64210Y679.029-48.386
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.1982.997+26.201
TTM100.3953.247+97.148
YOY610.9753.766+607.209
5Y630.6425.675+624.967
10Y679.0297.857+671.172

1.3. Liquidity of OBI Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if OBI Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.92 means the company has NT$19.92 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of OBI Pharma:

  • The MRQ is 19.923. The company is very able to pay all its short-term debts. +2
  • The TTM is 29.945. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.923TTM29.945-10.023
TTM29.945YOY28.467+1.478
TTM29.9455Y33.487-3.542
5Y33.48710Y33.632-0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.9233.930+15.993
TTM29.9454.251+25.694
YOY28.4675.436+23.031
5Y33.4876.045+27.442
10Y33.6326.363+27.269
1.3.2. Quick Ratio

Measures if OBI Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • A Quick Ratio of 11.91 means the company can pay off NT$11.91 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of OBI Pharma:

  • The MRQ is 11.912. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.912TTM7.928+3.985
TTM7.928YOY0.439+7.488
TTM7.9285Y2.177+5.751
5Y2.17710Y2.091+0.086
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9123.629+8.283
TTM7.9284.065+3.863
YOY0.4395.397-4.958
5Y2.1775.993-3.816
10Y2.0916.277-4.186

1.4. Solvency of OBI Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of OBI Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare OBI Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that OBI Pharma assets are financed with 11.6% credit (debt) and the remaining percentage (100% - 11.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of OBI Pharma:

  • The MRQ is 0.116. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.083. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.083+0.033
TTM0.083YOY0.070+0.013
TTM0.0835Y0.076+0.007
5Y0.07610Y0.075+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.332-0.216
TTM0.0830.334-0.251
YOY0.0700.268-0.198
5Y0.0760.366-0.290
10Y0.0750.390-0.315
1.4.2. Debt to Equity Ratio

Measures if OBI Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare OBI Pharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.1% means that company has NT$0.17 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of OBI Pharma:

  • The MRQ is 0.171. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.119. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.119+0.052
TTM0.119YOY0.094+0.025
TTM0.1195Y0.102+0.018
5Y0.10210Y0.099+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1710.381-0.210
TTM0.1190.390-0.271
YOY0.0940.334-0.240
5Y0.1020.434-0.332
10Y0.0990.466-0.367

2. Market Valuation of OBI Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings OBI Pharma generates.

  • Above 15 is considered overpriced but always compare OBI Pharma to the Biotechnology industry mean.
  • A PE ratio of -7.59 means the investor is paying NT$-7.59 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of OBI Pharma:

  • The EOD is -6.394. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.585. Based on the earnings, the company is expensive. -2
  • The TTM is 2.304. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-6.394MRQ-7.585+1.191
MRQ-7.585TTM2.304-9.889
TTM2.304YOY-13.634+15.938
TTM2.3045Y-15.385+17.689
5Y-15.38510Y-15.710+0.324
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.394-2.315-4.079
MRQ-7.585-2.560-5.025
TTM2.304-2.664+4.968
YOY-13.634-4.122-9.512
5Y-15.385-6.258-9.127
10Y-15.710-6.108-9.602
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of OBI Pharma:

  • The EOD is -7.350. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.719. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.781. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.350MRQ-8.719+1.369
MRQ-8.719TTM-10.781+2.062
TTM-10.781YOY-10.518-0.263
TTM-10.7815Y-19.104+8.322
5Y-19.10410Y-19.774+0.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.350-3.067-4.283
MRQ-8.719-3.251-5.468
TTM-10.781-3.545-7.236
YOY-10.518-5.595-4.923
5Y-19.104-8.315-10.789
10Y-19.774-8.708-11.066
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of OBI Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.21 means the investor is paying NT$3.21 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of OBI Pharma:

  • The EOD is 2.707. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.212. Based on the equity, the company is fair priced.
  • The TTM is 3.296. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.707MRQ3.212-0.504
MRQ3.212TTM3.296-0.084
TTM3.296YOY3.100+0.196
TTM3.2965Y4.872-1.576
5Y4.87210Y5.022-0.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7071.905+0.802
MRQ3.2122.111+1.101
TTM3.2962.095+1.201
YOY3.1002.836+0.264
5Y4.8723.443+1.429
10Y5.0223.794+1.228
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of OBI Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.410-1.290-46%2.470-198%0.105-2402%1.029-334%
Book Value Per Share--21.60725.020-14%28.081-23%23.405-8%23.220-7%
Current Ratio--19.92329.945-33%28.467-30%33.487-41%33.632-41%
Debt To Asset Ratio--0.1160.083+40%0.070+66%0.076+53%0.075+55%
Debt To Equity Ratio--0.1710.119+43%0.094+81%0.102+68%0.099+72%
Dividend Per Share----0%-0%-0%-0%
Eps---2.287-0.299-87%-1.760-23%-1.370-40%-1.389-39%
Free Cash Flow Per Share---1.990-1.921-3%-2.094+5%-1.720-14%-1.694-15%
Free Cash Flow To Equity Per Share---1.990-1.946-2%2.279-187%-0.317-84%-0.358-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--27.581--------
Intrinsic Value_10Y_min--20.241--------
Intrinsic Value_1Y_max---5.815--------
Intrinsic Value_1Y_min---5.716--------
Intrinsic Value_3Y_max---10.933--------
Intrinsic Value_3Y_min---10.569--------
Intrinsic Value_5Y_max---8.169--------
Intrinsic Value_5Y_min---8.145--------
Market Cap13411008000.000-19%15909811200.00018884304000.000-16%20007619200.000-20%25228742400.000-37%25735817142.857-38%
Net Profit Margin---28.469-59.974+111%-481.503+1591%-561.930+1874%-604.632+2024%
Operating Margin----14.0070%-599.1080%-538.3720%-590.2370%
Operating Ratio--29.198100.395-71%610.975-95%630.642-95%679.029-96%
Pb Ratio2.707-19%3.2123.296-3%3.100+4%4.872-34%5.022-36%
Pe Ratio-6.394+16%-7.5852.304-429%-13.634+80%-15.385+103%-15.710+107%
Price Per Share58.500-19%69.40082.375-16%87.275-20%110.050-37%112.262-38%
Price To Free Cash Flow Ratio-7.350+16%-8.719-10.781+24%-10.518+21%-19.104+119%-19.774+127%
Price To Total Gains Ratio-24.273+16%-28.796-15.041-48%-5.159-82%-38.862+35%-36.630+27%
Quick Ratio--11.9127.928+50%0.439+2612%2.177+447%2.091+470%
Return On Assets---0.094-0.044-53%-0.059-37%-0.062-34%-0.063-33%
Return On Equity---0.138-0.067-52%-0.080-42%-0.082-40%-0.083-40%
Total Gains Per Share---2.410-1.290-46%2.470-198%0.105-2402%1.029-334%
Usd Book Value--152566013.600176662532.200-14%198275723.800-23%165258652.020-8%163950275.867-7%
Usd Book Value Change Per Share---0.074-0.040-46%0.076-198%0.003-2402%0.032-334%
Usd Book Value Per Share--0.6660.771-14%0.865-23%0.721-8%0.715-7%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.070-0.009-87%-0.054-23%-0.042-40%-0.043-39%
Usd Free Cash Flow---14050220.800-13560785.700-3%-14785994.300+5%-12142242.420-14%-11960543.467-15%
Usd Free Cash Flow Per Share---0.061-0.059-3%-0.064+5%-0.053-14%-0.052-15%
Usd Free Cash Flow To Equity Per Share---0.061-0.060-2%0.070-187%-0.010-84%-0.011-82%
Usd Market Cap413059046.400-19%490022184.960581636563.200-16%616234671.360-20%777045265.920-37%792663168.000-38%
Usd Price Per Share1.802-19%2.1382.537-16%2.688-20%3.390-37%3.458-38%
Usd Profit---16150349.600-8057857.500-50%-12427153.200-23%-10743100.060-33%-10824137.867-33%
Usd Revenue--567305.200319927.300+77%36274.700+1464%318456.600+78%303698.267+87%
Usd Total Gains Per Share---0.074-0.040-46%0.076-198%0.003-2402%0.032-334%
 EOD+3 -5MRQTTM+7 -25YOY+8 -245Y+7 -2510Y+7 -25

3.2. Fundamental Score

Let's check the fundamental score of OBI Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.394
Price to Book Ratio (EOD)Between0-12.707
Net Profit Margin (MRQ)Greater than0-28.469
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.912
Current Ratio (MRQ)Greater than119.923
Debt to Asset Ratio (MRQ)Less than10.116
Debt to Equity Ratio (MRQ)Less than10.171
Return on Equity (MRQ)Greater than0.15-0.138
Return on Assets (MRQ)Greater than0.05-0.094
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of OBI Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.087
Ma 20Greater thanMa 5062.260
Ma 50Greater thanMa 10064.338
Ma 100Greater thanMa 20069.746
OpenGreater thanClose60.400
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets5,603,890
Total Liabilities650,448
Total Stockholder Equity3,806,731
 As reported
Total Liabilities 650,448
Total Stockholder Equity+ 3,806,731
Total Assets = 5,603,890

Assets

Total Assets5,603,890
Total Current Assets3,160,092
Long-term Assets2,443,798
Total Current Assets
Cash And Cash Equivalents 899,277
Short-term Investments 1,883,055
Net Receivables 6,477
Inventory 25,932
Total Current Assets  (as reported)3,160,092
Total Current Assets  (calculated)2,814,741
+/- 345,351
Long-term Assets
Property Plant Equipment 1,248,703
Long-term Assets Other 51,642
Long-term Assets  (as reported)2,443,798
Long-term Assets  (calculated)1,300,345
+/- 1,143,453

Liabilities & Shareholders' Equity

Total Current Liabilities158,618
Long-term Liabilities491,830
Total Stockholder Equity3,806,731
Total Current Liabilities
Short Long Term Debt 11,305
Accounts payable 773
Other Current Liabilities 3,253
Total Current Liabilities  (as reported)158,618
Total Current Liabilities  (calculated)15,331
+/- 143,287
Long-term Liabilities
Long term Debt 14,000
Capital Lease Obligations Min Short Term Debt475,748
Long-term Liabilities Other 3
Long-term Liabilities  (as reported)491,830
Long-term Liabilities  (calculated)489,751
+/- 2,079
Total Stockholder Equity
Total Stockholder Equity (as reported)3,806,731
Total Stockholder Equity (calculated)0
+/- 3,806,731
Other
Capital Stock2,294,394
Common Stock Shares Outstanding 229,248
Net Invested Capital 3,832,036
Net Working Capital 3,001,474
Property Plant and Equipment Gross 1,248,703



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
4,709,494
4,585,054
6,324,629
5,966,963
5,663,166
5,268,418
5,126,389
4,877,955
5,339,850
5,575,542
5,223,070
4,888,696
4,486,751
7,229,863
6,783,745
7,042,512
6,633,701
6,815,608
6,407,501
6,139,661
5,603,890
5,603,8906,139,6616,407,5016,815,6086,633,7017,042,5126,783,7457,229,8634,486,7514,888,6965,223,0705,575,5425,339,8504,877,9555,126,3895,268,4185,663,1665,966,9636,324,6294,585,0544,709,494
   > Total Current Assets 
3,793,229
3,564,370
5,334,434
5,004,413
4,705,976
4,335,476
4,228,362
4,013,619
3,894,812
4,141,582
3,748,399
3,346,953
2,854,137
5,543,014
5,091,293
5,383,470
5,034,081
5,271,575
3,776,079
3,518,352
3,160,092
3,160,0923,518,3523,776,0795,271,5755,034,0815,383,4705,091,2935,543,0142,854,1373,346,9533,748,3994,141,5823,894,8124,013,6194,228,3624,335,4764,705,9765,004,4135,334,4343,564,3703,793,229
       Cash And Cash Equivalents 
3,664,593
3,436,749
5,195,686
4,870,099
4,551,114
4,170,397
3,699,720
3,481,709
3,338,302
3,763,637
3,564,195
3,159,213
2,512,186
5,209,248
4,838,704
5,075,067
4,741,109
4,655,137
2,723,446
2,058,972
899,277
899,2772,058,9722,723,4464,655,1374,741,1095,075,0674,838,7045,209,2482,512,1863,159,2133,564,1953,763,6373,338,3023,481,7093,699,7204,170,3974,551,1144,870,0995,195,6863,436,7493,664,593
       Short-term Investments 
0
0
0
0
0
0
361,938
364,024
383,531
204,747
1,668
2,330
141,767
140,964
30,543
62,082
31,462
361,215
800,786
1,190,148
1,883,055
1,883,0551,190,148800,786361,21531,46262,08230,543140,964141,7672,3301,668204,747383,531364,024361,938000000
       Net Receivables 
38,088
1,087
1,234
569
39,195
44,886
26,651
26,033
19,018
16,284
21,262
19,971
23,269
6,392
13,616
20,858
28,273
3,284
28,458
4,954
6,477
6,4774,95428,4583,28428,27320,85813,6166,39223,26919,97121,26216,28419,01826,03326,65144,88639,1955691,2341,08738,088
   > Long-term Assets 
0
1,020,684
990,195
962,550
957,190
932,942
898,027
864,336
1,445,038
1,433,960
1,474,671
1,541,743
1,632,614
1,686,849
1,692,452
1,659,042
1,599,620
1,544,033
2,631,422
2,621,309
2,443,798
2,443,7982,621,3092,631,4221,544,0331,599,6201,659,0421,692,4521,686,8491,632,6141,541,7431,474,6711,433,9601,445,038864,336898,027932,942957,190962,550990,1951,020,6840
       Property Plant Equipment 
235,442
363,199
379,956
363,254
374,951
369,465
366,239
342,683
918,220
919,221
956,567
1,052,362
1,149,019
1,164,676
1,200,401
1,199,507
1,175,557
1,130,824
1,110,040
1,374,257
1,248,703
1,248,7031,374,2571,110,0401,130,8241,175,5571,199,5071,200,4011,164,6761,149,0191,052,362956,567919,221918,220342,683366,239369,465374,951363,254379,956363,199235,442
       Goodwill 
61,148
61,148
61,148
61,148
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000061,14861,14861,14861,148
       Long Term Investments 
7,454
8,560
7,311
7,141
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000007,1417,3118,5607,454
       Intangible Assets 
512,927
497,306
482,353
467,322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000467,322482,353497,306512,927
       Long-term Assets Other 
0
90,471
59,427
63,685
60,288
54,622
39,071
41,168
64,900
65,972
84,682
71,884
76,205
88,141
72,549
53,668
32,897
36,551
48,015
45,131
51,642
51,64245,13148,01536,55132,89753,66872,54988,14176,20571,88484,68265,97264,90041,16839,07154,62260,28863,68559,42790,4710
> Total Liabilities 
236,028
285,771
293,973
271,357
459,145
368,587
361,850
346,491
502,091
391,954
389,879
421,904
615,948
521,162
458,362
462,635
497,568
409,118
330,191
633,717
650,448
650,448633,717330,191409,118497,568462,635458,362521,162615,948421,904389,879391,954502,091346,491361,850368,587459,145271,357293,973285,771236,028
   > Total Current Liabilities 
103,817
61,138
78,444
67,487
200,004
114,048
121,550
176,653
248,488
147,236
105,212
117,723
327,224
204,580
156,342
171,210
221,138
143,148
109,013
123,911
158,618
158,618123,911109,013143,148221,138171,210156,342204,580327,224117,723105,212147,236248,488176,653121,550114,048200,00467,48778,44461,138103,817
       Short-term Debt 
9,853
9,818
9,782
9,747
9,711
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000009,7119,7479,7829,8189,853
       Short Long Term Debt 
9,853
9,818
9,782
9,747
9,711
9,675
9,000
0
9,468
43,468
9,832
10,128
7,000
7,000
5,705
12,709
22,705
13,726
8,935
11,305
11,305
11,30511,3058,93513,72622,70512,7095,7057,0007,00010,1289,83243,4689,46809,0009,6759,7119,7479,7829,8189,853
       Accounts payable 
0
0
0
0
0
0
0
0
157
689
695
679
525
251
2,278
331
1,144
162
4,724
3,511
773
7733,5114,7241621,1443312,27825152567969568915700000000
       Other Current Liabilities 
93,964
1,317
1,410
1,356
151,005
60,372
69,182
127,202
192,785
64,243
56,696
57,191
89,810
80,239
59,714
31,748
5,911
24,425
47,812
20,084
3,253
3,25320,08447,81224,4255,91131,74859,71480,23989,81057,19156,69664,243192,785127,20269,18260,372151,0051,3561,4101,31793,964
   > Long-term Liabilities 
0
224,633
215,529
203,870
259,141
254,539
240,300
169,838
253,603
244,718
284,667
304,181
288,724
316,582
302,020
291,425
276,430
265,970
221,178
509,806
491,830
491,830509,806221,178265,970276,430291,425302,020316,582288,724304,181284,667244,718253,603169,838240,300254,539259,141203,870215,529224,6330
       Capital Lease Obligations 
0
122,136
120,379
113,600
125,281
129,714
118,525
107,734
192,485
180,716
224,541
260,445
258,032
245,352
229,238
215,971
203,382
192,136
190,339
480,485
475,748
475,748480,485190,339192,136203,382215,971229,238245,352258,032260,445224,541180,716192,485107,734118,525129,714125,281113,600120,379122,1360
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
333333330000000000000
> Total Stockholder Equity
4,346,932
4,178,925
5,916,716
5,588,566
5,104,846
4,808,539
4,513,976
4,158,296
4,229,022
4,036,867
3,572,139
3,253,340
2,715,876
5,606,593
5,286,972
5,161,862
4,632,174
4,432,365
4,870,322
4,326,464
3,806,731
3,806,7314,326,4644,870,3224,432,3654,632,1745,161,8625,286,9725,606,5932,715,8763,253,3403,572,1394,036,8674,229,0224,158,2964,513,9764,808,5395,104,8465,588,5665,916,7164,178,9254,346,932
   Common Stock
1,739,907
1,731,287
1,881,287
1,881,287
1,881,287
1,882,287
1,882,287
1,885,862
1,992,794
1,992,794
1,992,794
1,992,794
1,992,794
2,292,794
2,292,794
2,292,794
2,294,394
0
2,294,394
0
0
002,294,39402,294,3942,292,7942,292,7942,292,7941,992,7941,992,7941,992,7941,992,7941,992,7941,885,8621,882,2871,882,2871,881,2871,881,2871,881,2871,731,2871,739,907
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 00-21,5040-26,323-14,720-20,303-19,904-24,528-26,399-22,194-16,794-16,788-18,166-16,469-20,766-22,392-21,521-20,817-19,883-21,417



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue41,549
Cost of Revenue-115,046
Gross Profit-73,497-73,497
 
Operating Income (+$)
Gross Profit-73,497
Operating Expense-2,131,340
Operating Income-2,089,791-2,204,837
 
Operating Expense (+$)
Research Development1,697,017
Selling General Administrative319,277
Selling And Marketing Expenses0
Operating Expense2,131,3402,016,294
 
Net Interest Income (+$)
Interest Income92,957
Interest Expense-7,937
Other Finance Cost-0
Net Interest Income85,020
 
Pretax Income (+$)
Operating Income-2,089,791
Net Interest Income85,020
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,275,554-2,089,791
EBIT - interestExpense = -7,937
-1,046,475
-1,038,538
Interest Expense7,937
Earnings Before Interest and Taxes (EBIT)0-1,267,617
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-1,275,554
Tax Provision--9,594
Net Income From Continuing Ops-1,265,960-1,265,960
Net Income-1,046,475
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-85,020
 

Technical Analysis of OBI Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of OBI Pharma. The general trend of OBI Pharma is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine OBI Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of OBI Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 59.40 < 60.50 < 65.20.

The bearish price targets are: .

Tweet this
OBI Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of OBI Pharma. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

OBI Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of OBI Pharma. The current macd is -1.11278768.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the OBI Pharma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for OBI Pharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the OBI Pharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
OBI Pharma Daily Moving Average Convergence/Divergence (MACD) ChartOBI Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of OBI Pharma. The current adx is 16.75.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell OBI Pharma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
OBI Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of OBI Pharma. The current sar is 65.37.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
OBI Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of OBI Pharma. The current rsi is 31.09. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
OBI Pharma Daily Relative Strength Index (RSI) ChartOBI Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of OBI Pharma. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the OBI Pharma price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
OBI Pharma Daily Stochastic Oscillator ChartOBI Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of OBI Pharma. The current cci is -171.9844358.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
OBI Pharma Daily Commodity Channel Index (CCI) ChartOBI Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of OBI Pharma. The current cmo is -46.6752633.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
OBI Pharma Daily Chande Momentum Oscillator (CMO) ChartOBI Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of OBI Pharma. The current willr is -93.90243902.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
OBI Pharma Daily Williams %R ChartOBI Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of OBI Pharma.

OBI Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of OBI Pharma. The current atr is 1.34541672.

OBI Pharma Daily Average True Range (ATR) ChartOBI Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of OBI Pharma. The current obv is -8,357,952.

OBI Pharma Daily On-Balance Volume (OBV) ChartOBI Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of OBI Pharma. The current mfi is 40.32.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
OBI Pharma Daily Money Flow Index (MFI) ChartOBI Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for OBI Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

OBI Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of OBI Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.087
Ma 20Greater thanMa 5062.260
Ma 50Greater thanMa 10064.338
Ma 100Greater thanMa 20069.746
OpenGreater thanClose60.400
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of OBI Pharma with someone you think should read this too:
  • Are you bullish or bearish on OBI Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about OBI Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about OBI Pharma

I send you an email if I find something interesting about OBI Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about OBI Pharma.

Receive notifications about OBI Pharma in your mailbox!